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Neuropilins (NRPs) are transmembrane receptors
that bind class 3 semaphorins and VEGF family mem-
bers to regulate axon guidance and angiogenesis. Al-
though expression of NRP1 by vascular smooth mus-
cle cells (SMCs) has been reported, NRP function in
smooth muscle (SM) in vivo is unexplored. Using
Nrp2/LacZ and Nrp2/gfp transgenic mice, we ob-
served robust and sustained expression of Nrp2 in the
SM compartments of the bladder and gut, but no ex-
pression in vascular SM, skeletal muscle, or cardiac
muscle. This expression pattern was recapitulated in
vitro using primary human SM cell lines. Alterations
in cell morphology after treatment of primary vis-
ceral SMCs with the NRP2 ligand semaphorin-3F
(SEMA3F) were accompanied by inhibition of RhoA
activity and myosin light chain phosphorylation, as
well as decreased cytoskeletal stiffness. Ex vivo con-
tractility testing of bladder muscle strips exposed to
electrical stimulation or soluble agonists revealed en-
hanced tension generation of tissues from mice with
548constitutive or SM-specific knockout of Nrp2, com-
pared with controls. Mice lacking Nrp2 also displayed
increased bladder filling pressures, as assessed by cys-
tometry in conscious mice. Together, these findings
identify Nrp2 as a mediator of prorelaxant stimuli in
SMCs and suggest a novel function for Nrp2 as a regu-
lator of visceral SM contractility. (Am J Pathol 2012, 181:
548–559; http://dx.doi.org/10.1016/j.ajpath.2012.04.013)
Neuropilins 1 and 2 (NRP1 and NRP2) are 130-kDa trans-
membrane receptors expressed on a range of cell types
that mediate the effects of two independent ligand fami-
lies: class 3 semaphorins (SEMA3) and members of the
vascular endothelial growth factor (VEGF) family. Interac-
tion of neuropilins with SEMA3 family members regulates
axonal guidance in the central and peripheral nervous
systems (reviewed by Bagri et al1). Neuropilins have
been shown to regulate angiogenesis by acting as core-
ceptors for VEGF on endothelial cells. Although both neu-
ropilins bind SEMA3 proteins, they display distinctive li-
gand binding preferences. SEMA3A binds preferentially
to NRP1, whereas SEMA3F binds with high affinity to
NRP2. Similarly, the VEGF binding profiles of NRP1 and
NRP2 are distinct: whereas both receptors bind VEGF-A,
only NRP2 binds VEGF-C and VEGF-D (reviewed by
Bielenberg and Klagsbrun2). Members of the plexin fam-
ily, in particular plexins A1 through A4, are also neces-
sary for SEMA3-mediated neuropilin-dependent signal-
ing. Binding of SEMA3 ligands to neuropilins initiates a
cascade of signals leading to marked changes in cell
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AJP August 2012, Vol. 181, No. 2shape, which in turn mediate repulsion of NRP-express-
ing cells from the SEMA3 source. Such alterations in
cell phenotype underlie the well-characterized growth
cone collapse that drives axon guidance,3,4 as well as
the antiangiogenic effects of SEMA3 ligands described
previously.5,6
The expression patterns for NRP1 and NRP2 are
largely nonoverlapping in vivo, suggesting discrete func-
tions for the two proteins. Transgenic overexpression of
Nrp1 resulted in embryonic lethality arising from excess
and dilated vessels, hemorrhage, and malformation of
the heart and limbs.7 Conversely, genetic ablation strat-
egies in mice and other experimental organisms revealed
functions for Nrp1 in neuron guidance and cardiovascu-
lar development.8–10 The demonstration that both over-
expression and deletion of Nrp1 evoke profound devel-
opmental abnormalities illustrates the requirement for
Nrp1 function during essential developmental processes,
but also suggests that NRP1 activity is dose-dependent.
Mice with targeted mutation of Nrp2 survive to adulthood,
but display aberrant development and/or organization of
cranial and spinal nerves, as well as a profound decrease
in lymphatic capillaries.11–14 Mice lacking both Nrp1 and
Nrp2 die early in embryonic development (embryonic day
8.5) as a result of impaired angiogenesis of the yolk sac
and other structures.15
Analyses of signaling pathways that underlie neuropi-
lin-mediated effects, such as collapse and inhibition of
migration, have identified Rho family G proteins as im-
portant regulatory nodes.16–18 We recently demonstrated
that SEMA3F signals via a NRP2-plexin A1 complex to
mediate cytoskeletal collapse in tumor and endothelial
cells.17 In that study, we identified ABL2/ARG and RhoA/
Rho kinase (ROCK) as components of a signaling cas-
cade leading to cofilin-mediated actin depolymerization
and an ensuing reduction in cell contractility and migra-
tion. RhoA and ROCK are also known regulators of
smooth muscle (SM) function, namely, the maintenance
of tone and contractility in vessels and other hollow or-
gans (reviewed by Puetz et al19). Although several re-
ports have described expression of NRP1 in vascular
smooth muscle cells (SMCs) and have identified a role for
NRP1 in regulation of SMC migration,20–23 the function of
neuropilins in SM in vivo has been unexplored. SEMA3-
dependent activation of neuropilins elicits effects on the
cytoskeleton similar to those seen with inhibition of the
Rho-ROCK axis. These observations imply that neuropi-
lins are important regulators of the SM phenotype and
provide a compelling rationale for determining their func-
tion in SM-rich hollow organs.
With the present study, we identify visceral SM as a
major site of expression of Nrp2 in vivo. Alterations in SM
phenotype contribute to various pathologies affecting
hollow organs, such as fibrosis and obstruction. Using a
combination of biochemical and functional evaluation of
cytoskeletal integrity, together with mouse models of
Nrp2 deficiency, we show that loss of Nrp2 in vivo en-
hances agonist-induced force generation in muscle
strips and leads to major alterations in hollow organ func-
tion. Collectively, these findings implicate Nrp2 as a novel
regulator of visceral SM contractility.Materials and Methods
Ethics Statement
All animal studies were performed with approval from the
Children’s Hospital Boston Animal Care and Use Commit-
tee and with strict adherence to US Public Health Service
and Office of Laboratory Animal Welfare guidelines.
Nrp2 Transgenic Mice
Nrp2/LacZ mice were generated as described previ-
ously.15 Briefly, a targeting vector was constructed in
which the translated portion of the first coding exon and
the proximal part of the next intron of Nrp2 were replaced
with a promoterless Escherichia coli -galactosidase gene
to produce Nrp2/LacZ mice. These mice were back-
crossed to the C57BL/6 strain for 10 generations. Pups
from heterozygous offspring mated to produce Nrp2LacZ/LacZ
(effectively, Nrp2/) die soon after birth. Nrp2/gfp mice
(also known as Nrp2tm1.2Mom/MomJ) were purchased
from the Jackson Laboratory (Bar Harbor, ME; stock no.
006700) and maintained in the C57BL/6 background.
Nrp2gfp/gfp mice were viable and fertile and were used for
contractility experiments. SM-specific deletion of Nrp2
after birth was accomplished by breeding mice harboring
an inducible Cre recombinase (CreERT2) under control of
the SM22 promoter (hereafter referred to as SM22-
CreERT2)24 to those expressing a floxed allele of Nrp2
(Nrp2fl/fl), and treating offspring positive for both geno-
types with 0.5 mg 4-hydroxytamoxifen (4-OHT) for 3 to 5
days. Tissues from mice were harvested for analysis at
selected times after initiation of recombination.
Histological Analysis and IHC
After euthanasia, whole Nrp2/LacZ newborn pups (postna-
tal day P1) or organs (bladder, heart, and skeletal muscle)
from Nrp2/LacZmice (P28 or P56) were directly embedded
in optimal cutting temperature compound (OCT: Sakura,
Tokyo, Japan) and frozen with liquid nitrogen. For detection
of -galactosidase activity, cryosections (8 to 10 m thick)
were fixed in cold methanol for 10 minutes,25 rinsed with
PBS (pH 7.2), and incubated overnight at 37°C in X-gal
reagent [1 mg/mL 5-bromo-4-chloro-3-indolyl--D-galacto-
pyranoside diluted in dimethyl sulfoxide, 5 mmol/L
K3Fe(CN)6, 5 mmol/L K4Fe(CN)6, and 2 mmol/L MgCl2 in
PBS (pH 6.5)]. The next day, sections were rinsed in PBS,
counterstained with eosin Y solution alcoholic with phloxine
(Sigma-Aldrich, St. Louis, MO), andmounted with Permount
medium (Thermo Fisher Scientific, Waltham, MA). For IHC
staining, cryosections were fixed in 2% paraformaldehyde
in PBS for 10 minutes (for mNrp2 staining), rinsed with PBS,
incubated in 3% H2O2 in methanol for 12 minutes to block
endogenous peroxidases, rinsed with PBS, incubated in
protein blocking solution (3% goat serum, 2% sheep serum
in PBS) for 15 minutes, and then incubated overnight at 4°C
in primary antibody (rabbit monoclonal (D39A5) anti-mouse
Nrp2 IgG antibody (3366; Cell Signaling Technology, Dan-
vers, MA) diluted in protein blocking solution. The next day,
for Nrp2 staining, sections were rinsed with PBS, incubated
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IgG (HL) antibody (Invitrogen-Life Sciences, Carlsbad,
CA) diluted in protein blocking solution, rinsed with PBS,
counterstained with Hoechst 33258 dye (bisbenzimide;
Sigma-Aldrich), and mounted with Fluoro-Gel medium
(Electron Microscopy Sciences, Hatfield, PA).
For -smooth muscle actin (-SMA) IHC staining, cryo-
sections were stained in a single-day procedure according
to the manufacturer’s instructions in a M.O.M. (Mouse-on-
Mouse) basic immunodetection kit (BMK-2202; Vector Lab-
oratories, Burlingame, CA) using mouse monoclonal anti--
SMA primary antibody (no. M0851, clone 1A4; Dako,
Carpinteria, CA). Sections were rinsed with PBS, incubated
for 1 hour in M.O.M. biotinylated anti-mouse IgG (Vector
Laboratories) diluted in protein blocking solution, rinsed with
PBS, incubated in horseradish peroxidase-conjugated avidin
(Vectastain Elite ABC kit, PK-6100; Vector Laboratories) for 30
minutes, washed with PBS, visualized with a 3,3=-diaminoben-
zidine peroxidase chromogenic substrate kit (SK-4100; Vector
Laboratories), rinsed with water, counterstained with Gill no. 3
hematoxylin (Sigma-Aldrich), andmountedwith Permountme-
dium. Control specimens exposed to each secondary anti-
body alone showed no specific staining.
Photomicrographs were obtained using Optronics En-
gineering image analysis software version 1.0.0.4 (Bio-
scan, Seattle, WA) and Adobe Photoshop software ver-
sion 5.0.2 installed in a PC microcomputer with a frame
grabber and with a Sony 3-CCD camera mounted on a
Nikon Eclipse E600 microscope. Scans of stained sec-
tions of newborn (postnatal day P1) mice were obtained
using a Polaroid SprintScan 35 Plus microscope slide
scanner (Meyer Instruments).
Cell Culture, Treatments, and Biochemical
Analyses
Human primary SMC cultures obtained from bladder
(HBSMC), colon (HCSMC), and bronchus (HBrSMC)
were purchased from ScienCell (San Diego, CA) and
propagated in smooth muscle cell medium (SMCM; Sci-
enCell). Human primary vascular SMCs obtained from
pulmonary artery (HPASMC), coronary artery (HCASMC),
or umbilical artery (HUASMC) were purchased from
Lonza (Walkersville, MD) and cultured in smooth muscle
growth medium (SmGM-2; Lonza). Spontaneously im-
mortalized porcine aortic endothelial (PAE) cells were
provided by Dr. Lena Claesson-Welsh (Uppsala Univer-
sity, Uppsala, Sweden) and maintained in F12 Ham’s
medium (Invitrogen-Life Technologies) supplemented
with 10% fetal bovine serum (FBS). PAE cells overex-
pressing NRP1 (PAE/NRP1) or NRP2 (PAE/NRP2) were
used as controls and described previously.5,26 Human
bladder urothelial cells were propagated in ProstaLife
medium (both from Lifeline Cell Technology, Frederick,
MD), according to the manufacturer’s guidelines.
For protein analysis, primary SMCs were seeded in
six-well plates at a density of 105 cells/well in complete
growth medium. For comparison of visceral and vascular
SMC protein content, lysates were harvested when cells
reached approximately 80% to 90% confluency in com-plete growth medium. For analysis of protein content after
growth factor treatment, cells were switched after 24
hours in complete growth medium to serum-depleted
medium for 24 hours, at which time growth factors were
added to a final concentration of 1 nmol/L for a further 24
hours. At the end of the incubation period, cells were
rinsed twice with ice-cold PBS and harvested in 1 lysis
buffer for protein analysis as described previously.27 In
selected experiments, membrane-enriched fractions
were prepared. Briefly, cells were rinsed twice with ice-
cold PBS, scraped in PBS and 2 mmol/L EDTA, and
pelleted at approximately 250  g at 4°C. Cell pellets
were resuspended in buffer M (50 mmol/L HEPES pH 7.4,
10 mmol/L NaCl, 5 mmol/L MgCl2, and 0.1 mmol/L EDTA
supplemented with protease inhibitors) and incubated for
10 minutes on ice, to promote cell swelling. Cells were
disrupted mechanically using a Potter-Elvehjem homog-
enizer; the resulting homogenates were centrifuged at
16,000  g for 10 minutes at 4°C, and pellets were
resuspended in buffer M containing 1% Triton X-100 and
incubated on ice for 30 minutes. Samples were centri-
fuged at 16,000  g for 15 minutes at 4°C and superna-
tants were assayed for protein content. For comparison of
protein content between various mouse organs, a wild-
type C57BL/6 mouse (age P56) was euthanized, and
organs were snap-frozen in liquid nitrogen. Frozen organs
were ground to a powder, and protein lysates were isolated
with radioimmunoprecipitation assay buffer (50mmol/L Tris-
HCl pH 7.5, 150 mmol/L NaCl, 1% NP40, 0.5% sodium
deoxycholate, and 0.1% SDS; Boston Bioproducts, Ash-
land, MA) supplemented with Complete Mini protease in-
hibitor cocktail (Roche Applied Science, Indianapolis, IN).
Protein concentrations were determined using a Bio-Rad
(Hercules, CA) DC protein assay kit.
RhoA activity assays were performed using a RhoA
activation assay kit based on rhotekin pull-down, accord-
ing to the manufacturer’s instructions (Cytoskeleton, Den-
ver, CO) and as described previously.17 Briefly, 1.5 106
cells HBSMCs were plated in full growth medium and
allowed to adhere overnight. Next, cells were incubated
with 320 ng/mL SEMA3F for 0 to 30 minutes, then were
washed with PBS and lysed with cell lysis buffer (25
mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 5 mmol/L
MgCl2, and 1% Triton X-100). Whole-cell lysates were
incubated with rhotekin-bound beads for 1.5 hours at 4°C
and washed with low-salt buffer (25 mmol/L Tris-HCl pH
7.5, 40 mmol/L NaCl, 15 mmol/L MgCl2). Proteins were
dissociated from beads by incubation in reducing sam-
ple buffer and were analyzed by Western blotting.
Western Blotting
Proteins were diluted in reducing sample buffer and re-
solved on 7.5% polyacrylamide gels or 4% to 20% gra-
dient polyacrylamide gels. Proteins were transferred to
nitrocellulose membranes and blocked with 5% nonfat
milk in Tris-buffered saline/Tween (50 mmol/L Tris-HCl pH
7.5, 150 mmol/L NaCl, and 0.05% Tween-20) for 1 hour.
For mouse proteins, the membrane was incubated over-
night at 4°C with rabbit monoclonal (D39A5) anti-mouse
Nrp2 IgG antibody (no. 3366; Cell Signaling Technology),
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phate dehydrogenase (GAPDH) IgG1 antibody (no.
MAB374; Millipore, Billerica, MA). For human proteins,
the membrane was incubated overnight at 4°C with one
of the following antibodies: mouse monoclonal (C-9) anti-
human NRP2 IgG2b antibody (no. SC-13117; Santa Cruz
Biotechnology, Santa Cruz, CA), mouse monoclonal (A-
12) anti-human NRP1 IgG1 antibody (SC-5307; Santa
Cruz Biotechnology), rabbit anti-plexin A1 polyclonal an-
tibody (3813; Cell Signaling Technology), rabbit mono-
clonal (67B9) anti-RhoA IgG antibody (2117; Cell Signal-
ing Technology), mouse monoclonal (MY-21) anti-myosin
light chain (MLC) IgM antibody (M4401; Sigma-Aldrich),
rabbit anti-phospho-MLC (pSer19) polyclonal antibody
(M6068; Sigma-Aldrich), mouse monoclonal (AC-15) anti-
-actin IgG1 antibody (A5441; Sigma-Aldrich), or anti-
calnexin polyclonal antibody (Abcam, Cambridge, MA).
Membranes were washed with Tris-buffered saline/
Tween and incubated in the appropriate secondary anti-
body, either horseradish peroxidase-linked donkey anti-
rabbit IgG whole antibody or horseradish peroxidase-
conjugated sheep anti-mouse IgG whole antibody (both
from GE Healthcare, Piscataway, NJ), for 1 hour. Membranes
were washed, exposed to enhanced chemiluminescence
(Pierce SuperSignal West Pico chemiluminescent substrate;
Thermo Fisher Scientific, Rockford, IL) and signals were visu-
alized after exposure of membranes to X-ray film.
RT-PCR
RNA was isolated from semiconfluent dishes of HBSMCs or
human bladder urothelial cells using TRIzol reagent (Invit-
rogen-Life Technologies) or from SM and urothelial com-
partments acquired by laser capture microdissection from
cryosections of bladders of C57BL/6 mice using Arcturus
PicoPure RNA isolation reagent (Life Technologies). RNA
was reverse-transcribed using a high-capacity cDNA syn-
thesis kit (Applied Biosystems-Life Technologies, Foster
City, CA), as described previously.27 cDNAs were amplified
using gene-specific primers for mouse and human neuro-
pilin 2 and semaphorin 3F (SABiosciences-Qiagen, Valen-
cia, CA), and relative mRNA levels were determined with
normalization to GAPDH, as described previously.27
Purification of SEMA3 Proteins
SEMA3F protein was purified as described previously.28
Briefly, HEK293 cells were transfected with human SEMA3F
plasmid (provided by Dr. Marc Tessier-Lavigne, Rockefeller
University) using FuGENE 6 transfection reagent (Roche
Applied Science). After 16 hours, the mediumwas replaced
with serum-free CD293 medium (Invitrogen-Life Technolo-
gies). Conditionedmedium containing SEMA3F protein was
collected after 48 hours, centrifuged, filtered, adjusted to
pH 7.4, purified over a HiTrap high-performance nickel
chelating column (GE Healthcare) using fast protein liquid
chromatography, eluted with imidazole-containing buffer,
and desalted using a PD-10 gel filtration column (GE
Healthcare). The resulting proteins were diluted in PBS (pH
7.2), and protein concentrations were established using a
Bio-Rad DC protein assay.Cell Collapse Assay
The SEMA3-induced cytoskeletal collapse assay was
modified from a previously reported assay28 for use with
HBSMCs or HCSMCs. Briefly, acid-washed glass cover-
slips (18  18 mm) were placed into six-well dishes.
HBSMCs or HCSMCs were plated onto the coverslips in
full growth medium. After 16 hours, purified SEMA3 pro-
teins (320 ng/mL) were added to half of the wells and
were incubated at 37°C. After 0 to 60 minutes, cells were
fixed in 4% paraformaldehyde in PBS for 10 minutes,
washed with PBS, permeabilized with 0.2% Triton X-100
(Sigma-Aldrich) in PBS for 5 minutes, washed with PBS,
stained with Alexa Fluor 488 phalloidin (1:250 dilution;
Invitrogen-Life Technologies) for 1 hour, washed with
PBS, counterstained with Hoechst 33258 dye, and
mounted with Fluoro-Gel medium (Electron Microscopy
Sciences). The actin cytoskeleton of the SMCs was visu-
alized and imaged using a Leica TCS SP2 AOBS confo-
cal laser scanning system attached to a Leica DM IRE2
inverted microscope (Leica Microsystems, Wetzlar, Ger-
many) and equipped with a 63 oil objective (NA 1.4), a
1.6 optivar, a 488-nm argon ion laser (for F-actin), and
a 405-nm diode (for nuclei). Differential interference con-
trast images were also obtained. Leica confocal software
LCS and ImageJ software (NIH, Bethesda, MD) were
used to scale recorded images. In selected experiments,
cells were pretreated with 10 mol/L Rho kinase inhibitor
Y27632 (EMD Chemicals, Darmstadt, Germany), 1
g/mL RhoA inhibitor C3 transferase (Cytoskeleton Inc.),
or 1 nmol/L HB-EGF.
Optical Magnetic Twisting Cytometry
Primary HBSMCs were seeded in 96-well plates at a density
of 10,000 cells/well; when confluent, cells were switched to
serum-depleted medium 24 hours before analysis. On the
day of measurement, cells were incubated with Arg-Gly-
Asp (R-G-D)-coated beads (4.5 m in diameter) for 20
minutes, to allow bead binding to integrins on the cell sur-
face. Vehicle, SEMA3F (0.2 or 0.6 g/mL), or Y27632 (10
M) was then added at the indicated concentrations for an
additional 40 minutes, after which plates were mounted on
a microscope stage custom fitted for twisting cytom-
etry.29–31 Briefly, beads were magnetized horizontally and
then twisted vertically in an oscillatory magnetic field with a
frequency of 0.75 Hz. From the ratio of the applied mechan-
ical torque to the measured lateral bead displacement, we
calculated the cell elastic modulus G=, a measure of cell
stiffness. For each experimental condition, data were
pooled from thousands of beads attached to hundreds of
cells from at least eight separate wells. Data are presented
as the median G= in pascals per nanometer  SEM.
Assessment of Bladder Function by Cystometry
To analyze bladder function in mice with constitutive
knockout of Nrp2, we performed conscious cystometry,
essentially as described previously.32 Briefly, Nrp2-null
mice and wild-type littermate controls were anesthetized
with isoflurane and the bladder was exposed with a lower
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(PE10) was placed in the dome of the bladder and se-
cured; the free end of the catheter was tunneled subcu-
taneously to the back of the mouse, where it was exteri-
orized. The abdominal incision was closed in two layers,
and animals were allowed to recover. The end of the
catheter was connected via a stopcock to an infusion
pump (Harvard Apparatus, Holliston, MA) and physiolog-
ical pressure transducer, and the bladder was filled with
normal saline solution at a rate of 12.5 L/minute. After an
equilibration period of 20 to 30 minutes, intravesical pres-
sure was monitored over multiple cycles of filling and
voiding during a 60-minute time frame. From these data,
parameters such as peak voiding pressure, intercontrac-
tion interval, and bladder compliance were determined.
Contractility Testing
Functional analysis of muscle strips was performed es-
sentially as described previously.33 Briefly, bladders from
female Nrp2 wild-type and null mice were harvested with
minimal handling into ice-cold Krebs solution (120
mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO3, 1.2
mmol/L Na2H2PO4, 1.2 mmol/L MgCl2 · 6H2O, 2.5 mmol/L
CaCl2, and 11.5 mmol/L dextrose). The bladders were
incised longitudinally, and the mucosa was removed by
dissection under a stereomicroscope. Tissue strips were
attached to a force transducer (Grass Technologies,
Quincy, MA) and were suspended in an organ bath main-
tained at 37°C and bubbled with a mixture of 95% O2 and
5% CO2. Bladder tissue was stretched to a force of 0.5 
g and equilibrated for 45 minutes. Contractile responses
to 1 nmol/L to 10 mol/L of the cholinergic agonist car-
bachol, 120 mmol/L KCl, and 10 mol/L --methyl-ATP
and to electrical field stimulation (1 to 64 Hz, 40 V, 0.5-ms
pulse width, 10-second duration) were measured in sep-
arate strips. Data were calculated as force (millinewtons)
normalized by tissue cross-sectional area and are ex-
pressed as means  SEM.
Statistical Analysis
Differences in contractile responses between Nrp2 wild-
type and Nrp2gfp/gfp mice were determined by Student’s
t-test. P  0.05 was considered significant. For analysis
of cystometric data, a generalized estimating equation
(GEE) model was used to analyze the differences between
Nrp2gfp/gfpmice andNrp2wild-typemice and also to handle
correlation of data obtained from the same mouse. Four
voids were obtained per mouse, for a total of 16 voids in
Nrp2gfp/gfp mice and 20 voids in Nrp2 wild-type mice.
Results
Neuropilin 2 Is Expressed in Visceral Smooth
Muscle in Vivo
To determine sites of expression of Nrp2 in vivo, we
used a genetic mouse model in which the gene encod-
ing bacterial -galactosidase (LacZ) replaces exon 1and the proximal part of intron 1 of the Nrp2 gene.15
Neonatal (P1) Nrp2/LacZ mice were euthanized and fro-
zen in optimal cutting temperature compound. Cryosec-
tions were stained with X-gal reagent to reveal robust
staining of the bladder and gastrointestinal tract (Fig-
ure 1A). Localization of Nrp2 signal to SM (Figure 1, B
and D) was verified by coincident immunostaining of
serial sections with an antibody to -SMA (Figure 1, C
and E). This staining pattern was reminiscent of that
reported by Chen et al,4 who noted high Nrp2 mRNA
levels in the presumptive bladder and gut during de-
velopment. Consistent with previous reports,11–13 X-gal
signal corresponding to Nrp2 was also detected in the
brain (Figure 1A). Expression of neuropilins is regu-
lated developmentally and is known to be down-regu-
lated after birth in vessels14 and neurons.34 To deter-
mine the postnatal expression pattern of Nrp2, tissues
from neonate and 4- and 8-week old Nrp2/LacZ mice
were stained with X-gal reagent, which revealed in-
tense staining of bladder and gut SM at P1, 4 weeks,
and 8 weeks (Figure 1, A, B, and D; see also Supple-
mental Figure S1, A–C, at http://ajp.amjpathol.org). This
observation suggests that regulation of Nrp2 in SM
differs from that in vessels and neurons and highlights
the robust expression of Nrp2 in this tissue type. We
confirmed expression of Nrp2 protein in the bladder
wall and gut by IHC staining and demonstrated local-
ization to SM, as described above (Figure 1F; see also
Supplemental Figure S1D at http://ajp.amjpathol.org);
importantly, no protein was detected in homozygous
null Nrp2LacZ/LacZ mice (Figure 1G).
Nrp2 expression in different organs was also assessed
by immunoblotting. In agreement with findings from X-gal
and Nrp2 immunostaining, this analysis revealed the
bladder and colon to display the highest levels of full-
length Nrp2, compared with expression in other tissues
(Figure 1H). To identify the predominant site of expres-
sion of Nrp2 within the bladder wall, we performed laser
capture microdissection coupled with real-time RT-PCR
of bladder tissue from three different strains of mice. We
observed significant enrichment of Nrp2 mRNA in SM,
relative to urothelium, whereas the Nrp2-selective ligand
Sema3F was enriched in urothelium, relative to SM (see
Supplemental Figure S1E at http://ajp.amjpathol.org).
Nrp2 was not detected in cardiac or skeletal muscle
(Figure 1A; see also Supplemental Figure S1, F–G at
http://ajp.amjpathol.org), although it was present in
-SMA-positive arrector pili muscle (see Supplemental
Figure S1H at http://ajp.amjpathol.org). Notably, Nrp2 was
absent from vascular SM (Figure 1J); however, Nrp2 was
expressed in endothelial cells of capillaries and veins (Fig-
ure 1J). Together, these data identify visceral SM as the
predominant site of Nrp2 expression in vivo.
Neuropilin 2 Is Expressed by Primary Visceral
SMCs in Vitro and Mediates Cytoskeletal
Rearrangement
To determine whether the expression pattern of Nrp2
observed in mice was recapitulated in humans, we inter-
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different sites, including bladder, colon, airways, and
both low- and high-resistance arteries. NRP2 expression
in vitro was evident in SMCs from bladder and colon, butwas weak in both pulmonary and coronary artery SMCs
(Figure 2A), which is in agreement with our in vivo obser-
vations (Figure 1, I versus J). Next, we determined the
expression level of plexins, a family of NRP2 coreceptors,
in human bladder and colon SMCs in vitro. Using RT-
PCR, we observed expression of plexin A1, but not plexin
A2 or A4, in bladder SMCs (data not shown). Plexin A1
and NRP2 protein expression were verified in membrane
preparations of bladder and colonic SMCs (Figure 2B).
We also examined expression of the NRP2 ligand
SEMA3F and found that, in contrast to NRP2 (which is
enriched in SMCs), SEMA3F was enriched in urothelial
cells (Figure 2C), consistent with our observations in
mouse bladder tissue (see Supplemental Figure S1E at
http://ajp.amjpathol.org).
Previous observations from our research group dem-
onstrated profound morphological changes in tumor cells
or endothelial cells after challenge with SEMA3F.17 To
assess whether SMCs undergo similar changes, cells
seeded on glass coverslips were exposed to SEMA3F and
cell morphology was assessed by staining with the actin-
binding agent phalloidin. SEMA3F elicited a marked cyto-
skeletal rearrangement in SMCs, characterized by thinning
of cells (Figure 2, E and G), compared with vehicle-treated
controls (Figure 2, D and F). These observations indicate
that NRP2 in human SMCs is functional.
Signals regulating NRP2 expression are largely un-
defined. To investigate NRP2 regulation in SMCs, we
exposed cells to agents that are known to regulate SM
phenotype. These include the SMC mitogens heparin-
binding EGF-like growth factor (HB-EGF)35 and plate-
let-derived growth factor (PDGF),36 as well as the prod-
ifferentiation factor transforming growth factor -1
(TGF--1).37 HB-EGF and PDGF markedly down-regu-
lated NRP2 protein levels in bladder and colonic
SMCs, but up-regulated expression of NRP1 (Figure
3A). In each case, PDGF caused greater NRP2 down-
regulation than HB-EGF, likely reflecting its higher ac-
tivity on SMCs.38 Conversely, TGF--1 stimulated
NRP2 expression in SMCs, but decreased NRP1 levels,
thus demonstrating differential regulation of neuropi-
lins in SMCs.
Figure 1. Neuropilin 2 is expressed in bladder and intestine. A: Cryosection of
a newborn (P1) Nrp2/LacZ mouse stained with X-gal reagent (blue) and coun-
terstained with eosin (pink) shows strong Nrp2 expression in the brain and
visceral organs. The bladder is marked by an asterisk. B–E: Cryosections of an
8-week-old Nrp2/LacZ mouse from bladder (B and C) or intestine (D and E)
stained with X-gal reagent [blue (B and D)] or anti-SMA [brown (C and E)] and
counterstained with eosin [pink (B and D) or hematoxylin [blue (C and E)]. In
bladder and intestine, Nrp2 expression was strongest in the muscle layer, but
was also found in endothelial cells (arrows). F and G:Neuropilin 2 localization
was assessed in cryosections of bladder from an 8-week-old heterozygous
Nrp2/LacZ mouse (F) and knockout Nrp2LacZ/LacZ mouse (G) using anti-Nrp2/
Hoechst 33258 (green/blue) staining.H:Western blot of whole-cell lysates from
organs of wild-type C57BL/6 mouse. Of the organs examined (liver, lung,
bladder, kidney, skin, heart, brain, and colon), the bladder expressed the highest
relative amount of Nrp2 and sNrp2 protein. Brain served as a positive control for
Nrp2, and GAPDHwas used as a loading control. I–K: X-gal staining [blue (I and
J)] or anti-SMA staining [brown (K)] of cryosections of 8-week-old Nrp2/LacZ
bladder (I) and a large artery and vein in the limb (J and K). Nrp2 is expressed
in visceral SM but not in vascular SM, and in venous but not arterial endothelial
cells. Scale bars: 1 mm (A); 0.1 mm (B–G); 0.1 mm (I–K).
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factor-mediated down-regulation of NRP2, we pre-
treated SMCs with PDGF or HB-EGF and determined
the effect of SEMA3F on cell shape. Although HB-EGF
alone did not alter SMC morphology (Figure 3, B versus
D), HB-EGF pretreatment prevented SEMA3F-induced
cytoskeletal rearrangement (Figure 3, C versus E). The
effect of PDGF on SEMA3F-induced changes could not
be assessed in this experiment, because PDGF pre-
treatment elicited significant changes in cell shape,
which masked the effect of SEMA3F. These findings
indicate that stimuli known to regulate SMC behavior
Figure 2. NRP2 is functional in human SMCs. A: Immunoblot of whole-
cell lysates from primary cultures of human SMCs isolated from different
organs. Visceral SMCs from bladder and colon expressed relatively higher
levels of NRP2 than vascular SMCs from pulmonary or coronary artery.
PAE/NRP2 and PAE/NRP1 served as a positive and negative control,
respectively; actin was used as a loading control. B: Human bladder and
colon SMCs have functional SEMA3F receptors. Immunoblot of membrane
fractions of HBSMCs and HCSMCs express the SEMA3F receptor NRP2 and
the coreceptor plexin A1. Calnexin protein expression was used as a
loading control for membrane protein. C: Relative expression of NRP2
and SEMA3F in HBSMCs or human bladder urothelial cells (HBUC) was
determined by semiquantitative RT-PCR. NRP2 and SEMA3F mRNA levels
in human bladder urothelial cells were set to a value of 1. D–G: HBSMCs
undergo cytoskeletal rearrangement after treatment with SEMA3F (600
ng/mL). Phalloidin staining (green) shows F-actin stress fibers (D and E)
and corresponding differential interference contrast images illustrate thin-
ning of the cells (F and G). Nuclei were stained with Hoechst 33258 dye
(blue). Original magnification, 100. HxSMC indicates human SMCs from
bladder (B), colon (C), umbilical artery (UA), pulmonary artery (PA),
bronchus (Br), and coronary artery (CA). PAE, porcine aortic endothelial
cells.modulate NRP function.Neuropilin 2 Regulates SMC Contractility via
RhoA/ROCK
Next, we interrogated signals downstream of the
SEMA3F-NRP2 axis that mediate alterations in SMC
morphology. The cytoskeletal rearrangement observed
after SEMA3F treatment (Figure 4, A and B) was phe-
nocopied by the addition of either the RhoA inhibitor
C3 transferase (Figure 4C) or the ROCK inhibitor
Y27632 (Figure 4D). Consistent with these observa-
tions, SEMA3F treatment led to inhibition of RhoA ac-
tivity (Figure 4E), as well as a reduction in myosin light
chain (MLC) phosphorylation (Figure 4F), correspond-
ing to decreased MLC activity. To determine whether
the cytoskeletal changes induced by SEMA3F were
associated with altered cytoskeletal stiffness, we per-
formed optical magnetic twisting cytometry.29,30 Expo-
sure of human SMCs to SEMA3F led to a dose-depen-
dent reduction in the cell elastic modulus G=, to an
extent similar to that obtained with the ROCK inhibitor
Figure 3. HB-EGF down-regulates NRP2 and inhibits the effects of
SEMA3F. A: HBSMCs and HCSMCs were treated with various growth
factors, and whole-cell lysates were examined by immunoblotting for
NRP1 and NRP2. PDGF and HB-EGF increased NRP1 but decreased NRP2.
TGF--1 decreased NRP1 but slightly increased NRP2. B–E: HBSMCs
pretreated with vehicle (B and C) or HB-EGF (D and E) were exposed to
SEMA3F (C and E) or not (B and D). Phalloidin staining (green) shows
F-actin stress fibers; nuclei were visualized with Hoechst 33258 dye
(blue). Original magnification, 100.
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in response to SEMA3F binding, NRP2 transduces sig-
nals that alter intracellular tension in SMCs in vitro
Figure 4. SEMA3F-induced changes in cell morphology are mediated via RhoA,
ROCK and MLC. A–D: Collapse assays using HBSMCs treated with vehicle (A),
SEMA3F (B), RhoA inhibitor (C3 transferase) (C), or ROCK inhibitor (Y27632) (D).
Phalloidin staining (green) shows F-actin stress fibers. Compounds inhibiting RhoA
or ROCK evoked similar changes in cell shape as SEMA3F. Original magnification,
100. E: SEMA3F inhibits RhoA activity in HBSMC. F: SEMA3F treatment leads to
decreased phosphorylation ofmyosin light chain (MLC) in humanbladder (HBSMC)
and colonic (HCSMC) SMCs. Cells were exposed to vehicle or SEMA3F (600 ng/mL)
for 30 minutes before immunoblotting with antibodies. G: SEMA3F treatment de-
creases the elastic modulus G= of HBSMCs in a dose-dependent manner. Cells
treated with 10 mol/L Y27632 (Y27) were included as a positive control. Data are
representative of at least two independent trials.through the Rho-ROCK axis.Neuropilin 2 Regulates Smooth Muscle
Contractility in Vivo
In view of the visceral SM-enriched expression pattern for
Nrp2 in mice and its ability to transduce prorelaxant sig-
nals in vitro, we next explored its potential function in vivo.
Because the bladder wall harbors the highest levels of
Nrp2 expression in vivo, we chose to analyze bladder
function as a representative system. For these analyses,
we used two complementary experimental approaches:
cystometry (for quantitative assessment of parameters
such as voiding pressure and presence/frequency of
nonvoiding contractions in intact, conscious mice) and ex
vivo contractility testing of bladder muscle strips (to mea-
sure force generation by tissue strips suspended under
isometric tension and exposed to contractile agonists).
Initially, we analyzed mice with constitutive knockout of
Nrp2 (Nrp2gfp/gfp) and compared them with age- and
sex-matched wild-type littermate controls (Nrp2/) (see
Supplemental Figure S2A at http://ajp.amjpathol.org). For
cystometry, PBS was infused at a defined rate (12.5 L/
minute) into the bladders of unrestrained wild-type and
Nrp2gfp/gfp mice via a catheter placed in the bladder 3
days before measurement. Bladder pressures were de-
termined over a period of approximately 60 minutes.
Overall, the voiding patterns of Nrp2-deficient mice did not
differ significantly from wild-type animals (Figure 5, A and
B). Notably, however, Nrp2gfp/gfp mice showed a greater
increase in intravesical (ie, bladder) pressure during the
filling phase of the cystometrogram (Figure 5B), com-
pared with wild-type mice (P  0.01) (Figure 5A). The
estimated mean compliance for Nrp2gfp/gfp mice was
6.34  1.86, whereas for wild-type mice it was 12.69 
1.67; the difference was statistically significant (P 
0.01). The reduced compliance in Nrp2gfp/gfp mice sug-
gested an abnormality in bladder wall elasticity and/or
contractility. Heterozygous Nrp2/gfp mice also displayed
an increased pressure change during filling, compared
with wild-type mice, but this did not reach statistical sig-
nificance (P  0.15) (data not shown).
We proceeded to investigate the contractile responses
of bladder tissue strips from wild-type or Nrp2gfp/gfp mice
to electric field stimulation or to exogenous soluble ago-
nists. Tissue strips from Nrp2gfp/gfp mice showed a signif-
icantly higher contractile response to electric field stimu-
lation at all frequencies tested, compared with those from
wild-type mice (P  0.05) (Figure 5C). Because the blad-
der SM response to electric field stimulation consists of
both cholinergic and purinergic components, we investi-
gated the responses to carbachol and --methylene-
ATP. The dose response to carbachol was also signifi-
cantly higher in Nrp2gfp/gfp mice at concentrations 30
nmol/L (P  0.05) (Figure 5D); however, the EC50 was
similar between groups (0.48  0.09 mol/L versus
0.46  0.07 mol/L), suggesting no alteration in receptor
density or sensitivity to agonist with Nrp2 deficiency. Pu-
rinergic stimulation also induced a greater contraction
from Nrp2gfp/gfp mice, compared with wild-type mice (P
0.025) (Figure 5E). Similarly, in bladder strips from
Nrp2gfp/gfp mice, contractions generated by direct stimu-
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greater than in tissue from wild-type mice (P  0.031)
(Figure 5F). These observations suggest that neuropilin 2
regulates SM contractility and that its loss enhances
bladder tissue contractility ex vivo.
To extend this analysis, we used Cre-LoxP technology
to delete Nrp2 specifically in SM, using the tamoxifen-
inducible SM22-CreERT2 strain.24 At selected time
points after the last injection of 4-OHT, mice were eutha-
nized and bladders were harvested for isometric tension
testing. Loss of Nrp2 expression in SM was highly effi-
cient, with little or no protein evident in SM tissue from
targeted animals, as determined by immunoblot analysis
of tissues (see Supplemental Figure S2B at http://ajp.
amjpathol.org) and by IHC staining (see Supplemental Fig-
ure S2, C versus D and E versus F, at http://ajp.amjpathol.
org). Contractility testing showed that bladder muscle
strips from mice with SM-specific Nrp2 deletion (SM-Cre:
Nrp2fl/fl) displayed enhanced force generation in res-
ponse to electric field stimulation, carbachol, -,meth-
ylene-ATP, or KCl, compared with tissue from nondeleted
controls (Nrp2fl/fl) (P  0.05) (Figure 6). These findings
are consistent with the increased contractility of bladderspecimens from mice with constitutive Nrp2 knockout
(Figure 5) and support the conclusion that Nrp2 regulates
visceral SM contractility.
Discussion
With this study, we provide the first demonstration of a
role for Nrp2 in regulation of SM contractility. Although
previous studies have reported expression of neuropilins
in isolated vascular SMCs and have demonstrated ex-
pression of Nrp2 mRNA in the developing bladder,4 none
described a role for these proteins in SM in vivo. Using a
series of complementary mouse models, including those
with constitutive or tissue-specific deficiency in Nrp2 ex-
pression, we show that the SM compartments of the blad-
der and gastrointestinal tract are among the sites with
highest expression of Nrp2 in vivo. Loss of expression of
Nrp2 in the bladder wall, either constitutively or in SM, led to
profound functional changes, marked by enhanced force
generation in response to a range of contractile agonists. In
Figure 5. Constitutive deletion of neuropilin 2
enhances SM contractility in vivo and ex vivo. A
and B: Representative cystometrograms showing
three voiding cycles of conscious unrestrained
mice in which Nrp2 is intact (wild-type; Nrp2/)
(A) or deleted (Nrp2gfp/gfp) (B). Data analysis re-
vealed decreased compliance in Nrp2-deficient an-
imals (P  0.01). C–F: Contractile responses of
bladder muscle strips from Nrp2-expressing and
Nrp2-deficient mice were determined in response
to electrical field stimulation (C), carbachol (D),
the ATP analog ,-me-ATP (E), and KCl (F). In
each case, force generation was higher in Nrp2gfp/gfp
mice. *P  0.05 (C and D); *P  0.025 (E); *P 
0.031 (F). n  5 mice per group (A); n  4 mice
per group (B); n  6 mice per group (C–F).addition, we observed a significant effect on the gastroin-
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and evidence of obstruction (data not shown).
Neuropilins are expressed in multiple cell types, includ-
ing neurons, vascular cells, dendritic cells, epithelial cells,
and SMCs. Several recent studies have described expres-
sion of both Nrp1 and Nrp2 in bladder epithelium and sub-
mucosa in vivo and have demonstrated changes in their
expression in response to inflammatory stimuli.39–42 Our
analysis of Nrp2 expression in vivo using the Nrp2/LacZ
and Nrp2/gfp reporter mice, together with immunofluo-
rescence imaging of wild-type mouse tissues, revealed
robust Nrp2 expression in SM but failed to detect signif-
icant Nrp2 expression in either bladder or gut epithelia.
Expression of neuropilins in many cell types is typically
down-regulated after birth, once the axonal guidance
and vascular development functions have been ful-
filled.14,34 However, we observed sustained expression
of Nrp2 in visceral SM in the postnatal period, consistent
with a function for Nrp2 in this location that is distinct from
its neurovascular roles.
The function of hollow organs such as the bladder and
gastrointestinal tract is to store waste products at low
pressure and expel them under volitional control. Serious
consequences can result from sustained increases in
intraluminal pressure, especially in the case of the blad-
der, with initial hypertrophy of the bladder wall leading to
fibrosis, transmission of elevated pressure to the kidneys
and ensuing renal damage. Our initial findings with tis-
sues from mice with constitutive knockout of Nrp2 re-
vealed increased contractility of bladder muscle strips
exposed to a range of contractile agonists, as well as
alterations in voiding behavior in conscious mice. In par-
ticular, analysis of voiding function in conscious mice
indicated a reduction in bladder compliance in Nrp2-
deficient animals, compared with controls. Decreasedcompliance in hollow organs can result from remodeling
and thickening of SM in response to elevated pressures,
as occurs secondary to bladder outlet obstruction, hy-
pertension, or asthma, and is characterized by aberrant
deposition and turnover of the extracellular matrix.43–45
Although we cannot exclude the possibility, our observa-
tion that neither peak voiding pressures nor bladder
weight in Nrp2-null mice differed significantly from wild-
type controls argues against the possibility that the re-
duced compliance observed in Nrp2-null mice results
from bladder outlet obstruction.
Because Nrp2 is expressed in multiple cell types of
relevance to bladder wall contractility, including SMCs
and neurons, initially it was not possible to ascribe the
enhanced force generation in tissues lacking Nrp2 to a
specific cell of origin. To address the contribution of
SM-expressed Nrp2, we deleted the gene selectively in
this tissue type, using SM22 to drive Cre recombinase.
The demonstration that Nrp2 deficiency specifically in SM
also led to enhanced contractility in muscle strips
strongly supports a myogenic, as opposed to neuro-
genic, mechanism for increased force generation. Our
analysis of laser capture-microdissected SM and urothe-
lial compartments from mouse bladders, as well as anal-
ysis of human bladder SMCs and urothelial cells in cul-
ture, revealed robust expression of SEMA3F in epithelial
cells, consistent with paracrine activation of NRP2 ex-
pressed on SMCs. It is important to note, however, that
the tension testing analysis was conducted in the ab-
sence of exogenous SEMA3F or VEGF.
The observation that tissue strips from Nrp2-null mice
showed enhanced responses to contractile agonists sug-
gests that Nrp2 may also interact functionally with canon-
ical regulators of contractility, such as muscarinic and
Figure 6. SM-specific deletion of neuropilin 2
enhances SM contractility ex vivo. Contractile
responses of SM strips from bladders of SM22-
Cre:Nrp2fl/fl mice (black symbols or bars) or
Nrp2fl/fl mice (gray symbols or bars), treated
with 4-OHT, were determined in response to
electrical field stimulation (A), carbachol (B), the
ATP analog ,-me-ATP (C), and KCl (D). In
each case, force generation was greater in
SM22-Cre:Nrp2fl/fl mice. *P  0.05 (A and B);
*P  0.033 (C); *P  0.008 (D). n  10 mice per
group, SM22-Cre:Nrp2fl/fl; n  5 mice per
group, Nrp2fl/fl.purinergic receptors and/or their effectors, independently
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domain of both Nrp1 and Nrp2 harbors the amino acids
Ser-Glu-Ala (S-E-A) at the C-terminus. This S-E-A motif
possesses PDZ domain binding activity and has been
shown to mediate interaction with the protein, neuropilin-
interacting protein (NIP), also known as synectin or
GIPC.46,47 GIPC in turn interacts with a number of pro-
teins associated with the contractile apparatus, including
transgelin/SM22, which is highly enriched in SM.48 No-
tably, Nrp1, acting through GIPC, was found to elicit
effects on endothelial cell spreading by modulating the
internalization and adhesion function of 51 integrin.49
Importantly, the ability of Nrp1 to affect 51 integrin
occurred independently of interactions with SEMA3 li-
gand and of its function as a VEGF coreceptor. Taken
together, these findings suggest that Nrp2 may regulate
SM contractility through both ligand-dependent and li-
gand-independent processes.
Activation of cholinergic and purinergic receptors, as
well as exposure of tissues to electrical field stimulation or
depolarizing agents such as KCl, can evoke a range of
different intracellular signals. All of them, however, are
known to activate the RhoA-ROCK axis to promote SM
contraction.50,51 Stimuli transduced by neuropilin 2 also
impinge on the RhoA-ROCK cascade. Data from primary
culture SMCs (Figure 3), as well as previous work from
our research group,17 showed that SEMA3F-mediated
signaling via NRP2 inhibited RhoA activity. In SMCs, this
led to decreased phosphorylation of MLC and a reduc-
tion in cytoskeletal stiffness as measured by optical mag-
netic twisting cytometry, consistent with stimulation of
relaxation. In contrast, inhibition of SEMA3F function in
vivo by genetic ablation of Nrp2 resulted in loss of relax-
ation (ie, increased contractility), compared with tissues
from controls with intact Nrp2.
Together, these observations are consistent with a
model in which Nrp2, through binding of SEMA3F, main-
tains appropriate SM tone, and loss of Nrp2 enhances
agonist-induced SM contractility by relieving inhibition on
RhoA/ROCK signaling.
In summary, we provide the first evidence to support a
role for Nrp2 in regulating contractility of visceral SM. The
ability of Nrp2 to promote SM relaxation, along with its
robust expression in hollow organs such as the bladder
and intestine, implies that this axis could be exploited for
therapeutic benefit in conditions characterized by inap-
propriate SM contractility. These include bladder and
bowel hyperreflexia secondary to spinal cord injury, as
well as gastrointestinal tract motility disorders such as
intestinal pseudo-obstruction and paralytic ileus. The ex-
istence of a natural ligand for Nrp2, as well as pharma-
cological agents that target components of the Nrp2 sig-
naling axis, suggests the potential for relatively rapid
translation of this novel finding to the clinical setting.
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